Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.

  title={Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.},
  author={Noriko Makita and Taroh Iiri},
  journal={Thyroid : official journal of the American Thyroid Association},
  volume={23 2},
BACKGROUND Thyroid dysfunction is a well-known adverse effect of sunitinib, a drug that targets multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR). As several kinds of tyrosine kinase inhibitors (TKIs) are now available, this has been postulated to be a side effect of the TKIs that target the VEGFR (VEGF-TKIs). However, sunitinib, one of the first-generation TKIs, likely causes thyroid dysfunction more frequently than other TKI classes, leading not… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
21 Citations
77 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 21 extracted citations


Publications referenced by this paper.
Showing 1-10 of 77 references

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

  • GR Blumenschein, Jr., +11 authors L Schwartzberg
  • Ann Oncol 22:2057–2067
  • 2011

Similar Papers

Loading similar papers…